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Abstract
Background: The purpose of this study was to examine whether ingesting a pre-workout dietary supplement
(PWS) with and without synephrine (S) during training affects training responses in resistance-trained males.
Methods: Resistance-trained males (N = 80) were randomly assigned to supplement their diet in a double-blind
manner with either a flavored placebo (PLA); a PWS containing beta-alanine (3 g), creatine nitrate as a salt (2 g),
arginine alpha-ketoglutarate (2 g), N-Acetyl-L-Tyrosine (300 mg), caffeine (284 mg), Mucuna pruiriens extract
standardized for 15% L-Dopa (15 mg), Vitamin C as Ascorbic Acid (500 mg), niacin (60 mg), folate as folic acid
(50 mg), and Vitamin B12 as Methylcobalamin (70 mg); or, the PWS supplement with Citrus aurantium extract
containing 20 mg of synephrine (PWS + S) once per day for 8-weeks during training. Participants donated a fasting
blood sample and had body composition (DXA), resting heart rate and blood pressure, cognitive function (Stroop
Test), readiness to perform, bench and leg press 1 RM, and Wingate anaerobic capacity assessments determined a
0, 4, and 8-weeks of standardized training. Data were analyzed by MANOVA with repeated measures. Performance
and cognitive function data were analyzed using baseline values as covariates as well as mean changes from
baseline with 95% confidence intervals (CI). Blood chemistry data were also analyzed using Chi-square analysis.
Results: Although significant time effects were seen, no statistically significant overall MANOVA Wilks’ Lambda
interactions were observed among groups for body composition, resting heart and blood pressure, readiness to
perform questions, 1RM strength, anaerobic sprint capacity, or blood chemistry panels. MANOVA univariate analysis
and analysis of changes from baseline with 95% CI revealed some evidence that cognitive function and 1RM
strength were increased to a greater degree in the PWS and/or PWS + S groups after 4- and/or 8-weeks compared
to PLA responses. However, there was no evidence that PWS + S promoted greater overall training adaptations
compared to the PWS group. Dietary supplementation of PWS and PWS + S did not increase the incidence of
reported side effects or significantly affect the number of blood values above clinical norms compared to PLA.
Conclusion: Results provide some evidence that 4-weeks of PWS and/or PWS + S supplementation can improve
some indices of cognitive function and exercise performance during resistance-training without significant side
effects in apparently health males. However, these effects were similar to PLA responses after 8-weeks of
supplementation and inclusion of synephrine did not promote additive benefits.
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Background
Research has shown that ingestion of some nutrients
and/or caffeinated beverages prior to exercise can im-
prove mental focus and/or exercise capacity [1]. For this
reason, a number of energy drinks and pre-workout sup-
plements (PWS) have been developed and marketed to
athletes. The primary ergogenic properties in most of these
supplements appears to be water, carbohydrate, and caf-
feine [1]. However, more recently PWS’s have been devel-
oped that not only contain nutrients that may affect acute
exercise performance (e.g., carbohydrate, caffeine, nitrates,
etc.), but also nutrients that can increase energy expend-
iture, reduce catabolism, and promote protein synthesis
thereby enhancing training adaptations when taken regu-
larly during training (e.g., amino acids, creatine, β-alanine,
etc.) [1–3]. Consequently, there has been increased interest
in examining the acute and chronic safety and efficacy of
PWS’s marketed to active individuals [4] as well as whether
adding potentially ergogenic nutrients may promote addi-
tive benefits [1].
This study examined the safety and efficacy of daily in-
gestion of a market leading PWS on ratings of percep-
tion of readiness to perform, cognitive function, resting
energy expenditure and metabolism, exercise perform-
ance, and markers of safety. The PWS studied contained
several nutrients reported to have ergogenic properties
including caffeine [5], beta-alanine [6], creatine [7], ni-
trate [8–11], arginine alpha-ketoglutarate [12] as well as
other nutrients purported to affect cognitive function
like tyrosine [13, 14] and Mucuna pruriens containing
L-Dopa [15, 16]. It is well established that consuming
caffeine prior to exercise (e.g., 3–6 mg/kg) can improve
exercise performance, cognitive function, and vigilance
[5]. A number of studies also indicate that ingestion of
nitrate prior to exercise (e.g., 300 mg) can improve exer-
cise capacity [9, 11, 17–20]. Theoretically, ingesting these
nutrients at effective doses prior to exercise may improve
cognitive function and vigilance leading to better workout
performance. If so, regular use of these types of PWS’s
may affect quality of training and/or training adaptations
particularly if they contain nutrients that have been re-
ported to enhance training adaptations like beta-alanine
[6, 21–27] and/or creatine [7, 28].
Citrus aurantium is found in the peel of bitter orange
and contains p-synephrine. Citrus aurantium (generally
containing 20–100 mg of synephrine) has been
purported to suppress appetite [29], increase resting en-
ergy expenditure and/or carbohydrate and fat oxidation
rates [30–33] and promote weight loss [34–36] with no
negative effects on the cardiovascular system [37–39].
There is also evidence that Citrus aurantium ingestion
can affect memory [40, 41] and resistance-exercise per-
formance [31]. Theoretically, adding Citrus aurantium
to a PWS may promote greater resting energy expend-
iture, cognitive function, and/or exercise capacity during
an exercise bout.
In an initial companion study that has been submitted
separately upon editor request [42–44], we reported that
acute ingestion of this PWS and PWS + S promoted
greater changes in resting energy expenditure, percep-
tions of vigor and energy, and cognitive function scores
compared to PLA. Therefore, the purpose of this study
was to examine the effects of ingesting a market leading
PWS with and without synephrine during 8-weeks of
resistance-training on ratings of perception of readiness
to perform, cognitive function, resting energy expenditure
and metabolism, exercise performance, and markers of
safety.
Methods
This study was conducted as a prospective, randomized,
double-blind, and placebo controlled cohort study. The
study was conducted at the Exercise & Sport Nutrition
Laboratory (ESNL) at Texas A&M University after
obtaining approval from the university’s Human Partici-
pant Internal Review Board.
Participant recruitment and familiarization
Apparently healthy, resistance-trained males were re-
cruited to participate from local advertisements. Inclu-
sion criteria required that each participant have at least
6 months of resistance training immediately prior to en-
tering the study inclusive of performing bench press and
leg press or squat. Participants were excluded if they
presented with a history of treatment for metabolic dis-
ease, hypertension, thyroid disease, arrhythmias, and/or
cardiovascular disease; and/or were currently using any
prescription medication. Further exclusion criteria in-
cluded an intolerance to caffeine and/or other natural
stimulants; a history of smoking; and, excessive alcohol
consumption (>12 drinks/week).
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A total of 213 individuals responded to advertisements
to participate in this study. Participants who met initial
study entry criteria via phone interview or online question-
naire screening were invited to a familiarization session
where the details of the study were explained, informed
consent was obtained, medical history was assessed, a fast-
ing blood sample was obtained, and a general medical exam
was performed by a registered nurse to determine eligibility
to participate in the study. A total of 122 individuals were
cleared to participate in the study and participated in a
familiarization session. This included explanation of the
protocol, instructions for completing the food record forms
and training program logs, and practicing the strength and
anaerobic capacity tests that were used in the study. Partici-
pants were then matched for age, body mass, and fat free
mass (FFM) and randomized into one of three dietary
supplement intervention arms in a randomized manner. A
total of 80 males (22 ± 4 y, 178 ± 6 cm, 80.9 ± 13.9 kg,
15.2 ± 0.7% fat, 25.6 ± 4.0 kg/m2) completed the study.
Strength training program
All participants were required to follow the same resist-
ance training routine. The resistance training program
consisted of training 4-days per week split into two
upper and two lower body workouts per week primarily
consisting of free-weight exercises for a total of 8-weeks.
The 8-week training protocol was periodized in 2–3 week
segments and consisted of selection from a list of 2–4
exercises for the following muscle groups: chest (two ex-
ercises for a total of six sets), back (two exercise for a
total of six sets), shoulders (one exercise for a total of
three sets), biceps (one exercise for a total of three sets),
triceps (one exercise for a total of three sets), abdomi-
nals (one exercise for a total of three sets), quadriceps
(two exercises for a total of six sets), hamstrings (two ex-
ercises for a total of six sets), and calves (one exercise
for three sets). Each exercise consisted of three sets of
ten repetitions (week 1–3), eight repetitions (week 4–6),
or six repetitions (week 7–8) performed with as much
weight as the participant could perform per set. The par-
ticipants recorded the amount of weight lifted during
each set of exercise on training log. A training partner
or fitness instructor provided signed verification that the
work out was completed as recorded. Prior research
from our lab has shown that this program is effective in
promoting significant strength and fat free mass gains
in resistance-trained athletes without nutritional inter-
vention [45].
Supplementation protocol
Participants were matched for age, body mass, and FFM
and randomly assigned to ingest in a double-blind man-
ner either: (1) a flavored dextrose placebo (PLA); (2) a
PWS containing beta-alanine (3 g), creatine nitrate as a
salt (2 g), arginine alpha-ketoglutarate (2 g), N-Acetyl-L-
Tyrosine (300 mg), caffeine (284 mg), Mucuna pruiriens
extract standardized for 15% L-Dopa (15 mg), Vitamin C as
Ascorbic Acid (500 mg), niacin (60 mg), folate as folic acid
(50 mg), and 70 mg of Vitamin B12 as Methylcobalamin
(Cellucor C4 Pre-Workout, Nutrabolt, Bryan, TX); or, 3.)
the PWS with Citrus aurantium (PWS+ S) extract stan-
dardized for 30% synephrine (20 mg) (Nutratech Inc.,
Caldwell, NJ). Supplements were independently packaged
by a third party into coded single foil packets for double-
blind administration following Good Manufacturing
Practices and certified to contain the aforementioned
ingredients by VMI Nutrition (Salt Lake City, UT). All
supplements had similar color and powdered texture.
Participants were instructed to ingest one foil packet per
day approximately 15–30 min prior to exercise on training
days and in the morning with breakfast on non-training
days. Supplement compliance was verified by weekly
compliance verification and collecting and counting
empty packets.
Testing sequence
Figure 1 shows the timeline of tests performed. Partici-
pants were instructed to refrain from exercise, caffeine,
and supplements containing stimulants for 48-h prior to
testing. Participants presented to the lab after a 12-h fast
and were required to provide a 4-days food-log that re-
corded their consumption of food and energy containing
Fig. 1 Study timeline
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fluids. Participants training logs were assessed by a
trained exercise physiologist to ensure compliance and
they submitted weekly side-effect questionnaires. Partici-
pants then donated ~ 20 ml of blood via venipuncture. Fol-
lowing blood sampling, we administered a series of tests.
This included determination of body weight, total body
water using bioelectrical impedance (BIA), body compos-
ition using dual-energy x-ray absorptiometry (DXA), resting
heart rate and blood pressure, cognitive function (Stroop
Word - Color test), perceptions of readiness to perform via
use of a visual analogue scale (VAS), one repetition max-
imum (1 RM) bench press, 1 RM leg press, and a 30s Win-
gate anaerobic capacity test on a cycle ergometer. Subjects
rested 5-min between bench press, leg press, and Wingate
tests as well as 2-min between sets on the bench press and
leg press. Participants completed these assessments at 0, 4,
and 8-weeks of training.
Procedures
Training assessment
Total lifting volume was calculated based on information
recorded on the training logs. This included multiplying
the amount weight lifted per set times the number repe-
titions completed for each exercise performed during
training sessions throughout the course of the study.
Total lifting volume for upper and lower extremity lifts
for the entire 8-week training period were calculated
and analyzed to evaluate training volume.
Diet assessment
Participants were provided a detailed description of how
to measure and record food and beverage intake on food
logs by a registered dietitian. Participants recorded all
food and energy containing fluids consumed for 4-days
(including 1 weekend day) prior to each testing session.
Food logs were checked for accuracy when returning to
the lab for each testing session and entered and analyzed
by a registered dietitian using dietary analysis software
(ESHA Food Processor Version 8.6, Salem, OR).
Side effect assessment
A questionnaire developed in our lab and reported in
numerous previously published papers [23, 46–49] was
used to assess side effects in this study. Participants
completed the survey every week throughout the study to
determine how well participants tolerated supplementa-
tion; how well participants followed the supplementation
protocol; and, if participants experienced any symptoms
during the supplementation period. Subjects were asked
to rank the frequency and severity of their symptoms for
dizziness, headache, fast or racing heart rate, heart skip-
ping or palpitations, shortness of breath, nervousness,
blurred vision, and unusual or adverse effects. Addition-
ally, participants ranked the frequency of symptoms with
0 (none), 1 (minimal: 1–2/week), 2 (slight: 3–4/week), 3
(occasional: 5–6/week), 4 (frequent: 7–8/week), or 5 (se-
vere: 9 or more/week) as well as severity of symptoms with
0 (none), 1 (minimal), 2 (slight), 3 (moderate), 4 (severe),
or 5 (very severe).
Body composition
Body mass and height were determined according to
standard procedures using a Healthometer Professional
500KL (Pelstar LLC, Alsip, IL, USA) self-calibrating digital
scale with an accuracy of ± 0.02 kg. Total body water
(TBW) was measured using bioelectrical impedance ana-
lysis (ImpediMed DF50, San Diego, CA) using standard pro-
cedures. Whole body bone density and body composition
measures (excluding cranium) were determined with a
Hologic Discovery W Dual-Energy X-ray Absorptiometer
(DEXA; Hologic Inc., Waltham, MA, USA) equipped with
APEX Software (APEX Corporation Software, Pittsburg, PA,
USA) by using procedures previously described [8, 50].
Mean test-retest reliability studies performed on male ath-
letes in our lab over repeated days revealed mean coeffi-
cients of variation (Cv) for total bone mineral content and
total fat free/soft tissue mass of 0.31–0.45% with a mean
intraclass correlation of 0.985 [51]. On the day of each test,
the equipment was calibrated following the manufacturer’s
guidelines.
Resting heart rate & blood pressure
As soon as the DXA scan was completed (about 6-min),
resting heart rate was determined in the supine position by
palpitation of the radial artery using standard procedures
[52]. Blood pressure was then assessed by auscultation of
the brachial artery using a mercurial sphygmomanometer
using standard clinical procedures [52].
Cognitive function assessment
Cognitive function was assessed using the Stroop Word-
Color test standardized by Golden [53]. The test consists
of three pages/tests with 100 items, presented in 5 col-
umns of 20 items. Items on the first page (Word) are the
color words RED, GREEN, and BLUE in black ink. On
the second page (Color) the items are XXX’s colored in
red, green, or blue ink. Items on the third page (Word-
Color) are the words RED, GREEN, and BLUE printed
in red, green, or blue ink with the limitation that word
and ink could not match. Participants were given stan-
dardized instructions and asked to read aloud each word
or color on each page as fast as they could for 45 s. The
number of correct responses obtained on each test dur-
ing the time period is used to assess cognitive function.
Readiness to perform assessment
Perceptions about readiness to perform were assessed
using a visual analogue scale (VAS) using a 5-item
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descriptive scale (strongly disagree, disagree, neutral,
agree, strongly agree) arranged on a 20 cm dotted bar
with these terms equidistant along the scale. Participants
were asked to respond to the following questions; “I
slept well last night”; “I am looking forward to today’s
workout”; “I am optimistic about my future perform-
ance”; “I feel vigorous and energetic”; “My appetite is
great”; and, “I have little muscle soreness”. Participants
circled the number or dot between numbers that best de-
scribed their current perceptions related to these
questions.
Strength testing
Strength tests were performed using an isotonic Olym-
pic bench press (Nebula Fitness, Versailles, OH) accord-
ing to standard procedures [45]. Participants followed a
warm-up consisting of 10 repetitions using 50% of their
estimated 1RM, 5 repetitions using 70% of their estimated
1RM, and 1 repetition using 90% of their estimated 1RM.
Participants were given 2-min recovery between attempts
and performed 1RM lifts until reaching a failure weight.
After 5-min recovery, participants warmed-up in a similar
fashion as described above and then performed 1RM lift
attempts on a standard hip sled/leg press (Nebula Fitness,
Versailles, OH) according to standard procedures [45].
Test to test reliability of performing these tests in our lab
on resistance-trained participants have yielded low Cv’s
and high reliability for the bench press (1.9%, r = 0.94) and
hip sled/leg press (0.7%, r = 0.91).
Anaerobic capacity testing
Prior to performing the anaerobic capacity test, partici-
pants warmed-up on a bicycle ergometer at a self-
selected work rate. Wingate anaerobic capacity tests
were performed using a Lode Excalibur Sport Ergometer
(Lode BV, Groningen, The Netherlands) with work rate
set at of 7.5 J/kg/rev. Participants were asked to pedal as
fast as possible prior to application of the workload and
sprint at an all-out maximal capacity for 30s. This test
measures absolute and relative peak and mean power
and total work. Test-to-test variability in performing re-
peated Wingate anaerobic capacity tests in our labora-
tory yielded a Cv of 15% with a test retest correlation of
r = 0.98 for mean power [47]. Participants practiced the
anaerobic capacity test during the familiarization session
to minimize learning effects.
Blood chemistry
All blood samples were analyzed for standard blood
chemistries inclusive of alkaline phosphatase (ALP), as-
partate transaminase (AST), alanine transaminase (ALT),
creatinine, blood urea nitrogen (BUN), creatine kinase
(CK), lactate dehydrogenase (LDH), glucose, and blood
lipids (total cholesterol, high density lipoprotein [HDL],
low density lipoprotein [LDL], triglycerides [TG]) using
a Cobas® c 111 (Roche Diagnostics, Basel, Switzerland).
The internal quality control for the Cobas® c 111 was
performed according to standard procedures [54] using
two levels of control fluids purchased from the manufac-
turer to calibrate to acceptable SD’s and Cv’s. Samples
were re-run if the observed values were outside control
values and/or clinical norms according to standard pro-
cedures. Test-to-test reliability assessment of assays eval-
uated in this study yielded mean CV’s < ±2.0% with r
values > 0.99. We also assessed a complete blood count
with platelet differential on whole blood (hemoglobin,
hematocrit, red blood cell counts, mean corpuscle vol-
ume (MCV), mean corpuscle hemoglobin (MCH), mean
corpuscle hemoglobin concentration (MCHC), red cell
distribution width (RDW), white blood cell counts, lym-
phocytes, granulocytes, and mid-range absolute count
(MID) using a Abbott Cell Dyn 1800 (Abbott Laboratories,
Abbott Park, IL, USA) automated hematology analyzer.
The internal quality control for Abbott Cell Dyn 1800 was
performed using three levels of control fluids to calibrate
to acceptable SD’s and Cv’s. Test-to-test reliability as-
sessment of assays evaluated in this study yielded mean
CV’s < ±6.3% with r values > 0.9.
Statistical analysis
Baseline demographic and training volume data were
analyzed by one-way analysis of variance (ANOVA). All
data were analyzed using general linear models (GLM)
multivariate analysis of variance (MANOVA) with repeated
measures with Wilks’ Lambda and Greenhouse-Geisser ad-
justments. For performance and cognitive function data,
baseline values were used as a covariate and run with
MANOVA for repeated measures with differences between
groups assessed using a Dunnet-Hsu post-hoc assessment
Table 1 Participant Demographics
Variable Group Number Means ± SD p-value
Age (y) PLA 27 22.3 ± 3.9 0.31
PWS 27 20.9 ± 3.9
PWS + S 26 22.0 ± 2.6
Height (cm) PLA 27 178.4 ± 6.9 0.64
PWS 27 177.0 ± 4.6
PWS + S 26 177.8 ± 5.6
Body Weight (kg) PLA 27 81.1 ± 13.3 0.94
PWS 27 81.5 ± 13.0
PWS + S 26 80.2 ± 15.8
BMI (kg/m2) PLA 27 25.4 ± 3.4 0.72
PWS 27 26.1 ± 4.6
PWS + S 26 25.4 ± 3.4
Values are means ± standard deviations. Variables were analyzed by
one-way ANOVA
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vs. the PLA condition. These data were also graphed with
means and 95% Confidence Interval (CI) to determine
whether changes from baseline were significant [55]. We
also analyzed the number of changes in blood chemistry
values observed from normal to exceeding normal clinical
limits from baseline to week 4, baseline to week 8 and week
4 to week 8 using a Chi-square analysis to examine whether
any nutritional treatment promoted a significant increase in
the number of participants with values exceeding normal.




Table 1 presents participant demographics by group as-
signment. A total of 80 participants completed the study
(PLA = 27, PWS = 27, PWS + S = 26). One-way ANOVA
revealed that no significant differences among groups in
baseline age, height, body weight, or body mass index.
Training volume and diet analysis
Table 2 presents total training volume observed among
groups for upper and lower extremity exercises. One-
way ANOVA analysis revealed that there were no signifi-
cant differences in lifting volumes among groups. Table 3
shows 4-day diet analysis data observed among groups
at 0, 4, and 8 weeks of training. MANOVA analysis re-
vealed that no significant group x time interactions were
observed among groups in relative energy intake (p = 0.19),
protein intake (p = 0.72), carbohydrate intake (p = 0.55) or
fat intake (p = 0.79).
Side effect analysis
Reported frequency and severity of dizziness, headaches,
racing heart rate, palpitations, shortness of breath, ner-
vousness, blurred vision, and/or other symptom were so
infrequent among participants that statistical analysis was
not valid as the vast majority of participants (i.e., 90–98%)
typically reported 0 ratings on each item throughout the
study. No study participant required medical referral.
Body composition
Table 4 presents body composition data observed during the
course of the study. MANOVA analysis revealed significant
time effects in changes in body weight (0.96 ± 2.6 kg, p=
0.003) and FFM 0.67 ± 1.8 kg, p= 0.001). However, no signifi-
cant interactions were observed among groups in body
weight (p= 0.28), fat mass (p= 0.61), FFM (p= 0.28), body fat
percentage (p= 0.36), or percent total body water (p= 0.37).
Resting heart rate & blood pressure
MANOVA analysis revealed no significant differences
among groups in hemodynamic responses during the
Table 2 Total Training Volume Data
Variable Group Number Total Volume p-value
Upper body (kg) PLA 25 279,831 ± 132,101 0.33
PWS 27 236,691 ± 87,062
PWS + S 23 269,928 ± 103,130
Lower body (kg) PLA 25 314,516 ± 136,966 0.66
PWS 27 283,825 ± 100,541
PWS + S 23 305,906 ± 133,611
Values are means ± standard deviations. Total training volume was analyzed
by one-way MANOVA. MANOVA analysis revealed overall Wilks’ Lambda group
(p = 0.69). p-values reported are with between-subjects effects
Table 3 Dietary Analysis Data
Variable Group Number Time (wk) p-value
0 4 8
Energy Intake (kcal/d/kg) PLA 26 27.06 ± 10.94 25.33 ± 9.31 24.72 ± 13.50 Group 0.27
PWS 25 30.15 ± 8.76 25.72 ± 8.10 26.29 ± 10.99 Time 0.29
PWS + S 23 29.03 ± 9.73 29.35 ± 13.75 32.13 ± 16.48 G x T 0.19
Protein (g/d/kg) PLA 26 1.48 ± 0.57 1.46 ± 0.64 1.49 ± 0.79 Group 0.18
PWS 25 1.54 ± 0.50 1.37 ± 0.47 1.51 ± 0.84 Time 0.86
PWS + S 23 1.74 ± 0.79 1.83 ± 1.13 1.77 ± 0.94 G x T 0.72
Carbohydrate (g/d/kg) PLA 26 2.60 ± 1.11 2.56 ± 0.95 2.21 ± 1.10 Group 0.91
PWS 25 2.87 ± 1.10 2.46 ± 1.02 2.30 ± 1.00 Time 0.008
PWS + S 23 2.61 ± 0.89 2.64 ± 1.43 2.42 ± 1.17 G x T 0.55
Fat (g/d/kg) PLA 26 1.05 ± 0.54 0.90 ± 0.41 0.98 ± 0.67 Group 0.14
PWS 25 1.22 ± 0.41 1.05 ± 0.45 1.14 ± 0.52 Time 0.30
PWS + S 23 1.19 ± 0.51 1.19 ± 0.84 1.30 ± 0.71 G x T 0.79
Values are means ± standard deviations. Total calories, Protein, Carbohydrate, and Fat intake were analyzed by MANOVA. MANOVA analysis revealed overall Wilks’
Lambda group (p = 0.04), time (p = 0.03), and group x time (p = 0.35). Greenhouse-Geisser time and group x time (G x T) interaction p-values are reported with
univariate group p-values
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study (Wilks’ Lambda group p = 0.62, time p = 0.33, and
group x time p = 0.87). Univariate analysis revealed no
indication that PWS or PWS+ S supplementation in-
creased resting heart rate (p = 0.26), systolic blood pressure
(p = 0.96), or diastolic blood pressure (p = 0.54) during
training compared to the PLA group. All group means
remained within ± 2 beats/min for heart rate and ± 2 mmHg
for blood pressure from baseline values.
Cognitive function assessment
Table 5 shows the results for cognitive function testing.
MANOVA analysis revealed Wilks’ Lambda overall time
effects (p < 0.001) with no significant interaction effects
(p = 0.17). MANOVA univariate analysis showed similar
trends. However, univariate ANOVA analysis revealed an
interaction trend (p = 0.087) among groups in color re-
sponses and a significant quadratic effect among groups
Table 5 Stroop Word-Color Cognitive Function Data
Variable Group Number Time (wk) p-value
0 4 8
Word (counts) PLA 27 109.8 ± 16.9 113.6 ± 17.2 116.2 ± 17.5 Group 0.33
PWS 27 107.7 ± 11.4 110.6 ± 10.9 115.3 ± 10.9 Time <0.001
PWS + S 26 102.3 ± 11.2 108.2 ± 17.0 112.4 ± 16.1 G x T 0.45
Mean ± SD 106.7 ± 13.7 110.8 ± 15.3* 114.7 ± 15.0*^
Color (counts) PLA 27 80.8 ± 10.6c 83.2 ± 11.8c 85.7 ± 12.5*c Group 0.35
PWS 27 78.2 ± 9.4 83.6 ± 9.6*c 86.7 ± 10.1*^c Time <0.001
PWS + S 26 77.0 ± 10.4a 79.7 ± 9.8*ab 82.1 ± 10.8*ab G x T 0.087l
Mean ± SD 78.7 ± 10.1 82.2 ± 10.5* 84.9 ± 11.2*^
Word-Color (counts) PLA 27 54.1 ± 11.5c 55.5 ± 11.5 58.5 ± 12.6*c Group 0.42
PWS 27 53.1 ± 5.9c 56.7 ± 7.4* 59.1 ± 7.6*c Time <0.001
PWS + S 26 49.2 ± 11.1ab 55.0 ± 9.6* 55.6 ± 10.2*ab G x T 0.04q
Values are means ± standard deviations. Word, Color, and Word-Color counts were analyzed by MANOVA. MANOVA analysis revealed overall Wilks’ Lambda group
(p = 0.83), time (p < 0.001), and group x time (p = 0.17). Greenhouse-Geisser time and group x time (G x T) interaction p-values are reported with univariate group
p-values. q represents quadratic effect and l represents linear p-value from univariate ANOVA. * represents p < 0.05 difference from baseline. ^ represents p < 0.05
difference from wk 4. arepresents p < 0.05 from PLA. brepresents p < 0.05 from PWS. crepresents p < 0.05 from PWS + S
Table 4 Body Composition Data
Variables Group Number Time (wk) p-value
0 4 8
Body Weight (kg) PLA 27 81.1 ± 13.4 81.8 ± 14.2 82.1 ± 14.0 Group 0.98
PWS 27 81.8 ± 13.3 81.3 ± 11.3 82.2 ± 12.8 Time 0.003
PWS + S 26 80.4 ± 16.1 81.3 ± 16.7 81.8 ± 17.3 G x T 0.28
Fat Mass (kg) PLA 27 11.3 ± 5.4 11.9 ± 5.5 11.9 ± 5.2 Group 0.75
PWS 27 12.7 ± 7.6 13.0 ± 7.7 12.8 ± 7.4 Time 0.10
PWS + S 26 11.3 ± 7.3 11.6 ± 8.3 11.5 ± 8.5 G x T 0.61
Fat-Free Mass (kg) PLA 27 63.0 ± 10.7 63.2 ± 11.2 63.4 ± 11.0 Group 0.94
PWS 27 62.3 ± 7.2 62.2 ± 6.7 62.7 ± 6.6 Time 0.001
PWS + S 26 62.4 ± 9.2 63.0 ± 9.0 63.6 ± 9.1 G x T 0.28
Body Fat (%) PLA 27 15.1 ± 6.2 15.7 ± 6.0 15.7 ± 5.6 Group 0.55
PWS 27 16.1 ± 6.6 16.4 ± 6.7 16.2 ± 6.3 Time 0.23
PWS + S 26 14.5 ± 5.8 14.5 ± 6.3 14.3 ± 6.1 G x T 0.36
Total Body Water (%) PLA 27 53.6 ± 6.4 53.0 ± 4.6 52.0 ± 5.5 Group 0.40
PWS 27 50.5 ± 5.5 51.0 ± 5.7 51.7 ± 6.3 Time 0.82
PWS + S 26 52.2 ± 5.7 51.4 ± 5.1 51.8 ± 5.9 G x T 0.37
Values are means ± standard deviations. All variables were analyzed by MANOVA. MANOVA analysis revealed overall Wilks’ Lambda group (p = 0.40), time (p = 0.003), and
group x time (p = 0.50). Greenhouse-Geisser time and group x time (G x T) interaction p-values are reported with univariate group p-values
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in Word-Color counts (p = 0.04). Post-hoc analysis re-
vealed that the PWS group demonstrated the greatest
change in color counts from baseline while changes in
word-color counts were seen sooner in the PWS and
PWS + S groups (4-weeks) compared to the PLA group.
Further, MANOVA analysis using baseline values as a
covariate revealed some differences among groups in
changes in cognitive function. As can be seen in Fig. 2,
mean changes in Color, Word, and Word-Color counts
where generally increased to a greater degree with 95%
CI’s above baseline in the PWS and/or PWS + S groups
compared to the PLA group values that were lower and
had 95% CI’s crossing baseline. After 8-weeeks of inter-
vention, all groups demonstrated significant increases in
Color, Word, and Color-Word counts. More specifically,
comparisons at week 4 demonstrated a significant in-
crease in Word count for the PLA (3.92 counts, 95% CI
.39, 7.45) and PWS + S (5.46 counts, 95% CI 2.09, 9.19)
group, but not for PWS (3.21 counts, 95% CI −0.31, 6.72).
By week 8, all groups increased their respective word
counts: PLA (6.74 counts, 95% CI 3.32, 10.16), PWS (7.56
counts, 95% CI 4.15, 10.97) and PWS + S (9.93 counts,
95% CI 6.49, 13.73). For the Color assessment comparison,
week 4 changes are: PLA (2.77 counts, 95% CI, 0.43, 5.09);
PWS (5.05 counts, 95% CI, 2.72, 7.38); and, PWS + S (2.57
counts, 95% CI, 0.24, 4.88). For week 8, color assessment
changes are: PLA (4.90 counts, 95% CI, 2.32, 7.46); PWS
(8.33 counts, 95% CI, 5.76, 10.89); and, PWS + S (5.08
counts, 95% CI, 2.51, 7.63). Week 4 word-color changes
were significant for the PWS (3.99 counts, 95% CI, 1.75,
6.23), and PWS + S (5.27 counts, 95% CI, 3.01, 7.52), but
not the PLA (2.08 counts, 95% CI, −0.15, 4.31) group. By
week 8, all groups demonstrated a significant increase in
word-color counts: PLA (5.02 counts, 95% CI, 2.44, 7.59);
PWS (5.84 counts, 95% CI, 3.27, 8.41); and, PWS + S (6.13
counts, 95% CI, 3.54, 8.72).
Readiness to perform assessment
Table 6 presents Readiness to Perform VAS data observed
throughout the study. MANOVA revealed an overall time
effect with no significant interactions among groups. Like-
wise, MANOVA using baseline values and age as a covari-
ate and analysis of mean changes with 95% CI’s revealed
no significant differences among groups.
Performance assessment
Performance testing outcomes are presented in Table 7.
MANOVA revealed significant time effects for bench press
and leg press 1RM performance. However, no significant
univariate interactions were observed among groups.
MANOVA analysis using baseline values as a covariate
and assessment of mean change and 95% CI’s of 1RM
strength data (Fig. 3) revealed that there were signifi-
cant increases in bench press 1RM strength at week 4
for the PWS (8.17 kg; 95% CI 1.88, 14.47) and PWS + S
(6.95 kg; 95% CI 0.62, 13.28), but not for the PLA
(5.45 kg, 95% CI −0.82, 11.73). By week 8, all groups
demonstrated a significant increase in BP 1 RM: PLA
(7.18 kg, 95% CI 1.01, 13.36), PWS (14.36, 95% CI 8.13,
20.59) and PWS + S (13.84 kg, 95% CI 7.64, 20.04). No
between group differences were noted at week 4 or
week 8. A similar pattern for leg press 1 RM strength
Fig. 2 Changes in Stroop Word (Panel a), Color (Panel b), and
Word-Color (Panel c) counts. Data are mean change and 95% CI
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Table 7 Performance Data
Variable Group Number Time (wk) p-value
0 4 8
Bench Press (kg) PLA 27 100.6 ± 20.8 102.9 ± 24.7 104.0 ± 23.3 Group 0.56
PWS 27 96.7 ± 23.1 99.2 ± 21.3 102.7 ± 21.7 Time <0.001
PWS + S 26 102.0 ± 16.3 106.2 ± 16.7 108.6 ± 17.1 G x T 0.33
Leg Press (kg) PLA 27 472.8 ± 149.8 490.3 ± 134.2 491.1 ± 131.0 Group 0.67
PWS 27 436.6 ± 96.6 466.0 ± 101.9 474.0 ± 96.3 Time <0.001
PWS + S 26 454.2 ± 79.4 474.4 ± 92.1 494.9 ± 100.9 G x T 0.28
Peak Power (Watt) PLA 27 1,472 ± 485 1,630 ± 475 1,507 ± 385 Group 0.91
PWS 27 1,502 ± 384 1,602 ± 354 1,603 ± 466 Time 0.01
PWS + S 26 1,445 ± 324 1,605 ± 444 1,544 ± 403 G x T 0.83
Mean Power (Watt) PLA 27 647 ± 146 640 ± 133 636 ± 127 Group 0.95
PWS 27 630 ± 72 643 ± 66 638 ± 69 Time 0.23
PWS + S 26 630 ± 114 656 ± 134 612 ± 145 G x T 0.40
Peak Power (Watt/kg) PLA 27 18.3 ± 5.6 20.2 ± 5.4 18.4 ± 4.0 Group 0.90
PWS 27 18.6 ± 4.7 19.8 ± 4.6 19.8 ± 5.8 Time 0.02
PWS + S 26 18.3 ± 3.6 20.2 ± 5.3 19.4 ± 4.8 G x T 0.80
Mean Power (Watt/kg) PLA 27 8.0 ± 1.1 7.9 ± 1.0 7.7 ± 0.9 Group 0.73
PWS 27 7.8 ± 1.2 8.0 ± 1.1 7.9 ± 1.0 Time 0.18
PWS + S 26 8.0 ± 1.1 8.2 ± 1.4 8.0 ± 1.2 G x T 0.33
Total Work (Joules) PLA 27 19,394 ± 4,377 19,217 ± 4,019 19,109 ± 3,826 Group 0.98
PWS 27 18,927 ± 2,166 19,319 ± 2,003 19,156 ± 2,095 Time 0.17
PWS + S 26 18,923 ± 3,431 19,680 ± 4,025 19,213 ± 3,110 G x T 0.29
Values are means ± standard deviations. Strength (Bench and Leg Press) were analyzed by MANOVA. MANOVA analysis revealed overall Wilks’ Lambda group (p= 0.58),
time (p< 0.001), and group x time (p= 0.29). Greenhouse-Geisser time and group x time interaction p-values are reported with univariate group p-values.
* represents p < 0.05 difference from baseline. ^ represents p < 0.05 difference from wk 4
Table 6 Readiness to Perform Visual Analogue Scale Data
Variable Group Number Time (wk) p-value
0 4 8
I slept well last night PLA 27 3.46 ± 0.90 3.43 ± 0.92 3.53 ± 0.90 Group 0.25
PWS 27 3.77 ± 0.93a 3.75 ± 0.89 3.52 ± 1.17 Time 0.83
PWS + S 26 3.21 ± 1.09b 3.26 ± 1.11 3.59 ± 0.91 G x T 0.34
I am looking forward to today’s workout PLA 27 3.93 ± 0.64 3.92 ± 0.61 3.63 ± 0.84 Group 0.94
PWS 27 3.85 ± 0.90 4.01 ± 0.68 3.77 ± 0.86 Time 0.22
PWS + S 26 3.73 ± 0.66 3.92 ± 0.68 3.93 ± 0.82 G x T 0.35
I am optimistic about my future performance PLA 27 4.39 ± 0.49 4.16 ± 0.66 3.71 ± 0.95 Group 0.25
PWS 27 4.50 ± 0.63 4.42 ± 0.63 4.05 ± 0.66 Time <0.001
PWS + S 26 4.21 ± 0.75 4.30 ± 0.67 3.88 ± 0.99 G x T 0.51
I feel vigorous and energetic PLA 27 3.56 ± 0.71 3.24 ± 0.75 3.21 ± 0.93 Group 0.26
PWS 27 3.46 ± 0.94 3.46 ± 0.84a 3.55 ± 0.73 Time 0.17
PWS + S 26 3.21 ± 0.80 3.00 ± 0.93b 3.38 ± 0.85 G x T 0.17
My appetite is great PLA 27 4.48 ± 0.64b 4.25 ± 0.81 4.17 ± 0.79 Group 0.13
PWS 27 4.03 ± 0.81c 4.03 ± 0.88 4.03 ± 0.79 Time 0.12
PWS + S 26 4.05 ± 0.92 3.96 ± 1.03 3.73 ± 1.11 G x T 0.63
I have little muscle soreness PLA 27 3.84 ± 0.73 3.84 ± 0.99 3.58 ± 1.04 Group 0.66
PWS 27 3.56 ± 1.15 3.67 ± 1.11 3.52 ± 1.00 Time 0.93
PWS + S 26 3.52 ± 1.17 3.52 ± 1.17 3.73 ± 1.11 G x T 0.68
Values are means ± standard deviations. Six questions were analyzed by MANOVA. MANOVA analysis revealed overall Wilks’ Lambda group (p = 0.27), time
(p < 0.001), and group x time (p = 0.66). Greenhouse-Geisser time and group x time (G x T) interaction p-values are reported with univariate group p-values.
* represents p < 0.05 difference from baseline. ^ represents p < 0.05 difference from wk 4. arepresents p < 0.05 from PLA. brepresents p < 0.05 from PWS.
crepresents p < 0.05 from PWS + S
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improvement was observed within the PWS (61.84 kg,
95% CI 24.96, 98.725) and PWS + S 44.89 kg, 95% CI
8.31, 81.47) groups, but not for PLA (36.50, 95% CI,
−0-21, 73.2). Similarly, by week 8, all groups increased
their LP 1RM as follows: PLA (43.28 kg, 95% CI 4.16,
82.41), PWS (79.23 kg, 95% CI 39.12, 118.54), and
PWS + S (89.54 kg, 95% CI 50.55, 128.53). No between
groups differences were noted at week 4 or week 8.
Similar results were observed in Wingate anaerobic
capacity assessment. MANOVA analysis using baseline
values and ages as covariates revealed that a significant
increase in Wingate peak power for PWS + S and PLA
at week 4; yet no significant differences were otherwise
noted at week 8 or among other Wingate parameters
examined.
Blood chemistry assessment
Tables 8, 9 and 10 show blood chemistry data analyzed
during the study. MANOVA revealed some time effects in
several variables indicative of individuals engaged in heavy
resistance exercise training with no significant group x
time interactions in muscle and liver enzymes, markers of
catabolism, or blood lipids. Univariate ANOVA analysis
revealed a significant quadratic effect in blood glucose
values. Post-hoc analysis revealed the PLA group had a
small but significant increase in blood glucose after 4-
weeks of training while all groups were higher after 8-
weeks of training. However, no significant differences
were seen among groups and values remained within
normal ranges. Table 11 shows Chi squared categor-
ical analysis. No significant differences were observed
among groups in the number of participants who
observed changes in blood chemistry markers above
normal baseline values.
Discussion
Numerous PWS’s are sold to athletes purporting to im-
prove acute exercise performance and/or promote
greater training adaptations [1]. Preliminary assessment
of the acute effects of ingesting the PWS used in this
study provided some evidence that this formulation en-
hanced resting energy expenditure and cognitive func-
tion and that adding 20 mg of synephrine to the
formulation increased resting energy expenditure to a
greater degree [42, 43]. Theoretically, use of these PWS’s
during training would promote greater fat loss and/or
training adaptations over time. Therefore, this study ex-
amined the safety and efficacy of daily ingestion of a
commercially available PWS with and without synephr-
ine for 8-weeks during training on body composition
and training adaptations in resistance-trained athletes.
Results indicated that while there was some evidence
that PWS ingestion enhanced some measures of cogni-
tive function and 1RM strength gains primarily after 4-
weeks of training, no significant differences were seen
among groups in improvement in body composition
and/or cognitive and exercise performance after 8-
weeks of training. Additionally, there was little evidence
indicating that adding synephrine to the PWS pro-
moted additive benefits. Results also indicated that
ingesting these PWS’s had no significant effects on
resting heart rate or blood pressure, standard clinical
chemistry panels, and/or the incidence of reported side
effects. Consequently, within the confines of this study,
use of these PWS’s appeared to be well-tolerated.
Cognitive function
The PWS’s investigated in this study contained 284 mg
of caffeine, 300 mg of N-Acetyl-L-Tyrosine, and 15 mg
of L-Dopa extracted from Mucuna pruiriens. Numerous
studies have shown that ingesting caffeine (e.g., 3–6 mg/
kg) can improve exercise performance, cognitive func-
tion, and/or vigilance [5]. In the present study, partici-
pants ingested an average of 3.5 mg/kg of caffeine prior
to training sessions. There is also some evidence that
tyrosine supplementation can improve cognitive
Fig. 3 Changes in 1RM bench press (Panel a) and 1RM leg press
(Panel b). Data are mean change and 95% CI
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function and/or memory [13, 14] although dosages typ-
ically studied (i.e., 50–150 mg/kg or 1.6–12 g) were
much higher than the amount investigated in this study
(i.e., 300 mg). Additionally, there is some evidence that L-
Dopa supplementation (e.g., 150 mg) can affect cognitive
function and/or reduce perceptions of fear or anxiety [15,
16] although the dosages studied in the present investiga-
tion are much lower. Thus, it is conceivable that ingesting
a PWS with ergogenic levels of caffeine (and possibly
tyrosine and/or L-Dopa) prior to exercise may provide
some improvement in cognitive function and/or train-
ing adaptations due to a greater ability to focus on ex-
ercise training.
In the present study, analysis of mean changes from
baseline with 95% CI’s (Fig. 2) indicated that change
in Stroop Color and Word-Color counts were signifi-
cantly above baseline in the PWS group and changes
in Word count, Color count, and Word-Color counts
were greater in the PWS + S group after 4-weeks of
training and these changes were generally greater
than the placebo group. These findings are consistent
with several studies that reported that acute or
chronic ingestion of PWS formulations containing
caffeine positively affected cognitive function, concen-
tration, and/or perceptions of energy [5, 56, 57]. The
Stroop Color-Word test assesses attention, processing
speed, and executive function which have been shown
to decline as one fatigues. Theoretically, maintaining
cognitive function during the latter stages of competi-
tion can improve performance particularly in events
that require quick decision making. However, after 8-
weeks of training and supplementation in the present
study, all groups observed similar improvements in
Stroop Word, Color, and Word-Color counts and no
differences were observed in questions related to
readiness to perform. These findings are consistent
with other studies reporting no overall benefit of
PWS supplementation on cognitive function, concen-
tration, and/or perceptions of energy [58, 59] and
suggest that the ergogenic value observed may lessen
over time. However, it is also possible that since per-
forming the 1 RM and anaerobic sprint capacity tests
Table 8 Muscle and Liver enzymes and Markers of Catabolism




PLA 27 76.8 ± 15.1 66.4 ± 12.9 71.2 ± 13.4 Group 0.24
PWS 27 87.2 ± 24.7 72.3 ± 19.0 78.4 ± 24.9 Time <0.001
PWS + S 26 76.4 ± 22.8 68.1 ± 17.3 74.4 ± 19.6 G x T 0.25
ALT
(U/L)
PLA 27 25.3 ± 10.0 25.0 ± 22.4 24.6 ± 13.0 Group 0.74
PWS 27 25.1 ± 10.1 26.9 ± 16.0 30.9 ± 17.9 Time 0.73
PWS + S 26 26.6 ± 23.0 28.6 ± 20.8 26.0 ± 12.2 G x T 0.55
AST
(U/L)
PLA 27 29.1 ± 11.0 27.6 ± 17.7 27.1 ± 9.8 Group 0.47
PWS 27 28.8 ± 9.7 31.6 ± 26.1 33.1 ± 19.7 Time 0.96
PWS + S 26 28.4 ± 15.1 28.4 ± 10.3 27.3 ± 8.5 G x T 0.76
CK
(U/L)
PLA 27 310.0 ± 217.2 263.1 ± 214.4 215.5 ± 115.1 Group 0.34
PWS 27 297.5 ± 160.4 256.9 ± 203.7 336.1 ± 242.0 Time 0.79
PWS + S 26 261.2 ± 130.0 324.1 ± 232.2 274.8 ± 172.3 G x T 0.86
LDH
(U/L)
PLA 27 164.2 ± 36.2 153.5 ± 33.9 159.4 ± 29.5 Group 0.90
PWS 27 157.7 ± 24.2 160.7 ± 37.6 162.8 ± 24.3 Time 0.19
PWS + S 26 158.8 ± 32.1 152.5 ± 24.3 160.4 ± 23.6 G x T 0.44
BUN
(mg/dl)
PLA 27 14.9 ± 4.9 b 12.3 ± 6.7 16.2 ± 6.8 Group 0.62
PWS 27 12.0 ± 4.0 c 12.3 ± 5.8 16.1 ± 5.3 Time <0.001
PWS + S 26 13.6 ± 4.9 12.6 ± 6.6 16.5 ± 5.0 G x T 0.55
Creatinine
(mg/dl)
PLA 27 1.15 ± 0.44 0.72 ± 0.47 0.85 ± 0.36a Group 0.27
PWS 27 1.08 ± 0.41 0.75 ± 0.38 0.95 ± 0.31 Time <0.001
PWS + S 26 1.13 ± 0.51 0.82 ± 0.43 1.05 ± 0.28c G x T 0.78
BUN:Creatinine PLA 27 15.7 ± 9.6 24.7 ± 19.1 26.5 ± 23.4 Group 0.20
PWS 27 12.7 ± 6.8 22.7 ± 17.3 20.4 ± 15.0 Time 0.002
PWS + S 26 15.3 ± 10.9 20.9 ± 15.1 17.9 ± 12.6 G x T 0.63
Values are means ± standard deviations. All variables were analyzed by MANOVA. MANOVA analysis revealed overall Wilks’ Lambda group (p = 0.43), time
(p < 0.001), and group x time (p = 0.66). Greenhouse-Geisser time and group x time (G x T) interaction p-values are reported with univariate group p-values.
* represents p < 0.05 difference from baseline. ^ represents p < 0.05 difference from wk 4
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did not require significant executive or cognitive
functioning to perform, there may be benefits on
other performance tasks that require more decision
making and attention.
Training adaptations
The PWS’s examined in the present study contained a
number of nutrients that have been purported to influence
training adaptations. For example, the PWS’s contained
3 g/day of beta-alanine. Beta-alanine supplementation
(e.g., 3–6 g/day for 2–4 weeks) has been reported to in-
crease muscle carnosine levels, buffer acidity, and enhance
exercise performance [6, 21–24]. Research has indicated
that length of time of supplementation affects the impact
that beta-alanine supplementation has on muscle carno-
sine levels and potential ergogenic benefit [27, 60–62].
Thus, it is possible that consuming 3 g/day of beta-alanine
for 8-weeks could have provided ergogenic benefit during
resistance-training. The PWS supplements also contained
2 g/day of creatine nitrate at approximately a 2:1 ratio of
creatine to nitrate. While there is little evidence that
ingesting 2 g/day of creatine for 8-weeks can markedly in-
crease muscle creatine stores and/or affect exercise cap-
acity, it is enough creatine to maintain creatine stores
during training [7, 28]. The greater potential of ergogenic
value from ingesting 2 g/day of creatine nitrate would the-
oretically be due to the nitrate content [46, 63]. There are
a number of studies that indicate that nitrate supplemen-
tation prior to exercise (e.g., 300 mg) can improve exercise
capacity [9, 11, 17–20]. The amount of nitrate contained
in the creatine nitrate supplement used (i.e., ~1 g/day) is
more consistent with dietary recommendations to help
control blood pressure [64, 65]. Nevertheless, there was
sufficient amount of nitrates in the PWS to provide some
ergogenic benefit particularly to endurance exercise per-
formance. The PWS’s also contained 2 g/day of arginine
alpha-ketoglutarate. Prior research has reported that diet-
ary supplementation of higher doses of arginine alpha
keto-glutarate (e.g., 12 g/day) can affect exercise capacity
[12] although other studies with lower amounts have
shown no benefit [66, 67]. Given that the PWS’s only con-
tained 2 g/day of arginine alpha-ketoglutarate, it is likely
that this nutrient provided minimal effects. Finally, one of
the PWS’s contained 20 mg of synephrine (as Citrus Aur-
antium). Synephrine has been purported to suppress ap-
petite [29] and promote weight loss through an enhanced
thermogenesis [34–36] with no negative effects on the car-
diovascular system [37, 38, 68]. Theoretically, adding
synephrine to the PWS would promote greater fat loss
during training and a more optimal body composition.
Table 9 Blood Glucose and Lipid Data




PLA 27 86.6 ± 7.0 93.7 ± 12.8* 93.8 ± 13.0* Group 0.90
PWS 27 89.4 ± 7.1 89.7 ± 8.9 95.1 ± 9.2* Time <0.001
PWS + S 26 90.7 ± 8.2 90.1 ± 5.0 95.4 ± 7.9* G x T 0.017q
Cholesterol
(mg/dl)
PLA 27 159.5 ± 31.6 156.9 ± 34.3 156.1 ± 41.7 Group 0.34
PWS 27 164.1 ± 31.3 158.1 ± 26.0 163.3 ± 32.8 Time 0.16
PWS + S 26 174.5 ± 42.8 171.9 ± 40.9 165.9 ± 36.1 G x T 0.44
HDL-C
(mg/dl)
PLA 27 53.4 ± 12.6 51.8 ± 13.1 51.3 ± 15.0 Group 0.99
PWS 27 52.7 ± 14.7 50.0 ± 13.9 52.6 ± 14.7 Time 0.10
PWS + S 26 53.5 ± 16.2 52.7 ± 12.7 49.6 ± 15.0 G x T 0.24
CHL:HDL PLA 27 3.1 ± 0.7 3.1 ± 0.8 3.1 ± 0.7 Group 0.38
PWS 27 3.2 ± 0.9 3.3 ± 0.8 3.2 ± 0.7 Time 0.35
PWS + S 26 3.9 ± 3.7 3.5 ± 1.8 4.1 ± 4.4 G x T 0.22
LDL-C
(mg/dl)
PLA 27 106.0 ± 29.6 105.0 ± 31.4 104.7 ± 35.1 Group 0.32
PWS 27 111.4 ± 29.8 108.0 ± 23.4 110.6 ± 27.9 Time 0.43
PWS + S 26 121.0 ± 35.2 119.2 ± 42.3 116.2 ± 42.2 G x T 0.56
Triglyceride
(mg/dl)
PLA 27 74.2 ± 33.8 81.9 ± 31.5 83.6 ± 30.7 Group 0.11
PWS 27 92.8 ± 43.3 98.5 ± 37.8a 86.5 ± 37.6 Time 0.89
PWS + S 26 81.6 ± 36.6 73.9 ± 22.9b 80.4 ± 41.9 G x T 0.31
Values are means ± standard deviations. All variables were analyzed by MANOVA. MANOVA analysis revealed overall Wilks’ Lambda group (p = 0.44), time
(p < 0.001), and group x time (p = 0.58). Greenhouse-Geisser time and group x time (G x T) interaction p-values are reported with univariate group p-values.
q represents quadratic effect and l represents linear p-value from univariate ANOVA. * represents p < 0.05 difference from baseline. ^ represents p < 0.05
difference from wk 4
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Results of the present study provide some support that
ingesting a PWS containing these nutrients enhanced
training adaptations. Analysis of mean changes from
baseline and 95% CI data (see Fig. 4) indicated that there
was some evidence that 1RM strength gains were greater
with PWS supplementation compared to placebo at both
4 and 8-weeks of training. There was also evidence that
peak power, mean power, and total work during the an-
aerobic capacity sprint test was increased to a greater
degree after 4-weeks of PWS + S supplementation (see
Fig. 4). However, consistent with findings from Outlaw
and colleagues [58], we did not observe a significant im-
provement in body composition changes in response to
training as has previously been reported [56, 69]. This
includes when adding 20 mg of synephrine (as Citrus
Aurantium) to the formulation. These latter findings
contrast reports suggesting that that Citrus Aurantium
supplementation can promote weight and/or fat loss
[36, 70] although it should be noted that the amount of
synephrine provided (i.e., 20 mg/day) was less than that
used in Kaats et al. study (i.e., 49 or 98 mg/day). Greenway
and coworkers [71] reported that ingesting an herbal
supplement containing 200 mg of green tea, 198 mg of
caffeine (derived from guarana extract), and 9 mg of
synephrine (derived from Citrus Aurantium) did not
promote weight loss. Thus, it is possible that a higher
dose of synephrine is needed to promote weight loss in
individuals involved in intense training and/or addition
of synephrine to a PWS has less effect in resistance-
trained individuals.
Table 10 Complete Blood Count Data




PLA 27 6.09 ± 2.09 5.84 ± 1.17 6.04 ± 1.52 Group 0.36
PWS 27 6.64 ± 1.54 6.21 ± 1.66 5.92 ± 1.17 Time 0.09
PWS + S 26 5.98 ± 1.25 5.66 ± 1.40 5.68 ± 1.74 G x T 0.64
RBC Count
(x106/μl)
PLA 27 5.09 ± 0.72 4.82 ± 0.47 4.87 ± 0.54 Group 0.72
PWS 27 4.92 ± 0.51 4.92 ± 0.51 4.88 ± 0.34 Time 0.88
PWS + S 26 4.87 ± 0.60 5.04 ± 0.56 5.05 ± 0.64 G x T 0.16
Hemoglobin
(g/dl)
PLA 27 15.55 ± 2.49 14.90 ± 1.35 15.12 ± 1.46 Group 0.84
PWS 27 15.24 ± 1.33 15.26 ± 1.76 15.03 ± 0.95 Time 0.97
PWS + S 26 14.84 ± 2.13 15.60 ± 1.78 15.61 ± 1.98 G x T 0.13
Hematocrit
(%)
PLA 27 47.28 ± 6.86 44.66 ± 4.31 45.04 ± 5.08 Group 0.76
PWS 27 45.84 ± 4.71 45.74 ± 5.60 45.45 ± 3.07 Time 0.85
PWS + S 26 45.24 ± 5.77 46.87 ± 5.22 46.77 ± 5.77 G x T 0.16
MCV
(fL)
PLA 27 92.87 ± 3.89 92.72 ± 3.51 92.48 ± 3.61 Group 0.34
PWS 27 93.22 ± 3.37 92.98 ± 3.28 93.18 ± 2.86 Time 0.32
PWS + S 26 92.74 ± 3.03 92.98 ± 3.26 92.60 ± 3.27 G x T 0.37
MCH
(pg/cell)
PLA 27 30.53 ± 1.76 30.98 ± 2.09 31.12 ± 1.81 Group 0.80
PWS 27 31.06 ± 1.44 31.07 ± 1.53 30.83 ± 1.48 Time 0.13
PWS + S 26 30.37 ± 1.33 30.96 ± 1.24 30.93 ± 1.60 G x T 0.36
MCHC
(g/dl)
PLA 27 32.87 ± 1.39 33.40 ± 1.46 33.69 ± 1.90 Group 0.73
PWS 27 33.34 ± 1.35 33.41 ± 1.42 33.09 ± 1.22 Time 0.11
PWS + S 26 32.75 ± 0.91 33.31 ± 1.37 33.39 ± 1.10 G x T 0.30
RDW
(%)
PLA 27 13.38 ± 0.62c 13.28 ± 0.51 12.98 ± 0.59 Group 0.43
PWS 27 13.09 ± 0.58 13.11 ± 0.88 13.18 ± 0.73 Time 0.65
PWS + S 26 12.97 ± 0.58a 12.99 ± 0.77 13.08 ± 0.72 G x T 0.02
Platelet Count
(x103/μl)
PLA 27 220.66 ± 75.84 233.14 ± 53.34 228.96 ± 55.60 Group 0.46
PWS 27 230.77 ± 45.80 234.11 ± 38.24 242.92 ± 41.94 Time 0.58
PWS + S 26 222.53 ± 67.23 222.26 ± 48.51 217.38 ± 51.95 G x T 0.65
Values are means ± standard deviations. All variables were analyzed by MANOVA. MANOVA analysis revealed overall Wilks’ Lambda group (p = 0.78), time
(p = 0.06), and group x time (p = 0.013). Greenhouse-Geisser time and group x time (G x T) interaction p-values are reported with univariate group p-values. arepre-
sents p < 0.05 from PLA. brepresents p < 0.05 from PWS. crepresents
p < 0.05 from PWS + S
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Table 11 Prevalence of Blood Chemistry Changes Exceeding Normal Clinical Bounds
Marker Category PLA PWS PWS + S p-value
Lipids & Glucose Cholesterol No Change 23 24 25 0.42
Normal Baseline, Exceed at 4-weeks 2 0 1
Normal Baseline, Exceed at 8-weeks 0 1 0
Normal 4-weeks, Exceed 8-weeks 2 2 0
HDL-C No Change 25 21 26 0.10
Normal Baseline, Exceed at 4-weeks 1 1 0
Normal Baseline, Exceed at 8-weeks 1 1 0
Normal 4-weeks, Exceed 8-weeks 0 4 0
LDL-C No Change 15 15 17 0.49
Normal Baseline, Exceed at 4-weeks 11 9 9
Normal Baseline, Exceed at 8-weeks 1 1 0
Normal 4-weeks, Exceed 8-weeks 0 2 0
Triglycerides No Change 27 27 25 0.35
Normal Baseline, Exceed at 4-weeks 0 0 1
Normal Baseline, Exceed at 8-weeks 0 0 0
Normal 4-weeks, Exceed 8-weeks 0 0 1
Glucose No Change 21 23 24 0.49
Normal Baseline, Exceed at 4-weeks 2 0 0
Normal Baseline, Exceed at 8-weeks 1 1 0
Normal 4-weeks, Exceed 8-weeks 3 3 2
Muscle LDH No Change 20 18 18 0.74
Normal Baseline, Exceed at 4-weeks 1 2 0
Normal Baseline, Exceed at 8-weeks 2 1 3
Normal 4-weeks, Exceed 8-weeks 4 6 5
Creatine Kinase No Change 19 22 21 0.42
Normal Baseline, Exceed at 4-weeks 1 0 0
Normal Baseline, Exceed at 8-weeks 0 1 2
Normal 4-weeks, Exceed 8-weeks 7 4 3
Kidney Creatinine No Change 23 25 23 0.72
Normal Baseline, Exceed at 4-weeks 2 0 1
Normal Baseline, Exceed at 8-weeks 0 0 0
Normal 4-weeks, Exceed 8-weeks 2 2 2
BUN No Change 17 18 19 0.41
Normal Baseline, Exceed at 4-weeks 3 2 1
Normal Baseline, Exceed at 8-weeks 0 0 2
Normal 4-weeks, Exceed 8-weeks 7 7 4
Liver ALP No Change 25 23 25 0.28
Normal Baseline, Exceed at 4-weeks 1 0 0
Normal Baseline, Exceed at 8-weeks 0 0 0
Normal 4-weeks, Exceed 8-weeks 1 4 1
ALT No Change 24 22 22 0.72
Normal Baseline, Exceed at 4-weeks 1 0 0
Normal Baseline, Exceed at 8-weeks 1 2 1
Normal 4-weeks, Exceed 8-weeks 1 3 3
AST No Change 23 21 21 0.84
Normal Baseline, Exceed at 4-weeks 1 1 1
Normal Baseline, Exceed at 8-weeks 0 1 2
Normal 4-weeks, Exceed 8-weeks 3 4 2
Data are frequency of occurrence. Significance is by chi-square analysis
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Safety analysis
One of the criticisms regarding PWS’s is that while there
may be some ergogenic benefit, the short and/or long-
term safety of taking these supplements is unknown [1].
Results of the present investigation indicate that the
PWS’s studied were well-tolerated and did not adversely
affect markers of health. In this regard, we observed no
significant changes in resting hemodynamics, clinical
blood markers, or a disproportional number of reported
side effects in the PWS groups. These findings are con-
sistent with a growing body of evidence that PWS sup-
plementation appears to be safe and well-tolerated in
apparently healthy individuals [56–59, 69, 70, 72–78]
and that combination of these types of nutrients in PWS
does not pose undue risk.
Conclusions
Results suggest that 8-weeks of PWS and PWS + S sup-
plementation can improve some indices of cognitive
function and exercise performance during resistance-
training without significant side effects in apparently
healthy males. However, the inclusion of synephrine did
not promote additive benefits. Additional research should
investigate the effects of ingesting PWS’s on cognitive and
exercise performance, training adaptations, and safety of
long-term use in athletes.
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